Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Mechanisms of Disease: oxidative stress and inflammation in the pathogenesis of hypertension

Nature Clinical Practice Nephrology volume 2, pages 582–593 (2006)Cite this article

Abstract

Animal studies have shown that oxidative stress and renal tubulointerstitial inflammation are associated with, and have major roles in, the pathogenesis of hypertension. This view is supported by the observations that alleviation of oxidative stress and renal tubulointerstitial inflammation reduce arterial pressure in animal models. Conversely, hypertension has been shown to cause oxidative stress and inflammation in renal and cardiovascular tissues in experimental animals. Taken together, these observations indicate that oxidative stress, inflammation and arterial hypertension participate in a self-perpetuating cycle which, if not interrupted, can lead to progressive cardiovascular disease and renal complications. These events usually occur in an insidious and asymptomatic manner over an extended period following the onset of hypertension. Severe target organ injury can, however, occasionally occur precipitously in the course of malignant or accelerated hypertension. Given the high degree of heterogeneity of hypertensive disorders, the factor(s) initiating the vicious cycle described vary considerably in different forms of hypertension. For instance, oxidative stress in the kidney and vascular tissue is the primary mediator in the pathogenesis of angiotensin-induced, and perhaps lead-induced, hypertension. By contrast, increased arterial pressure is probably the initiating trigger in salt-sensitive hypertension. Although the initiating factor might vary between hypertensive disorders, according to the proposed model, the three components of the cycle eventually coalesce in all forms of hypertension.

Key Points

  • Oxidative stress, inflammation and arterial hypertension participate in a self-perpetuating cycle that can lead to progressive cardiovascular and renal disease

  • The initiating pathogenic factor in this cycle differs in different forms of hypertension

  • Therapeutic strategies should aim to reduce production of reactive oxygen species rather than involving mere administration of antioxidant agents

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The self-perpetuating cycle involving oxidative stress and inflammation in the pathogenesis of hypertension.
Figure 2: Interplay between tubulointerstitial inflammation, the intrarenal renin–angiotensin system and oxidative stress in the hypertensive kidney.
Figure 3: Effect of oxidative stress on nitric oxide metabolism in the kidney, brain and cardiovascular tissues, and its impact on arterial blood pressure.
Figure 4: The role of renal tubulointerstitial inflammation in pathogenesis of salt-sensitive hypertension and hypertension.

Similar content being viewed by others

References

  1. World Health Organization, International Society of Hypertension Writing Group (2003) World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21: 1983–1992

  2. Mueller CF et al. (2005) ATVB in focus: redox mechanisms in blood vessels. Arterioscler Thromb Vasc Biol 25: 274–278

    Article  CAS  PubMed  Google Scholar 

  3. Sen CK (2001) Antioxidant and redox regulation of cellular signaling: introduction. Med Sci Sports Exerc 33: 368–370

    Article  CAS  PubMed  Google Scholar 

  4. Taniyama Y and Griendling KK (2003) Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 42: 1075–1081

    Article  CAS  PubMed  Google Scholar 

  5. Griendling KK et al. (2000) NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86: 494–501

    Article  CAS  PubMed  Google Scholar 

  6. Chabrashvili T et al. (2002) Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 39: 269–274

    Article  CAS  PubMed  Google Scholar 

  7. Griendling KK (2004) Novel NAD(P)H oxidases in the cardiovascular system. Heart 90: 491–493

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Lassegue B and Clempus RE (2003) Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 285: R277–R297

    Article  CAS  PubMed  Google Scholar 

  9. Hehner SP et al. (2000) Enhancement of T cell receptor signaling by mild oxidative shift in the intracellular thiol pool. J Immunol 165: 4319–4328

    Article  CAS  PubMed  Google Scholar 

  10. Los M et al. (1995) Hydrogen peroxide as a potent activator of T lymphocyte functions. Eur J Immunol 25: 159–165

    Article  CAS  PubMed  Google Scholar 

  11. Sen CK and Packer L (1996) Antioxidant and redox regulation of gene transcription. FASEB J 10: 709–720

    Article  CAS  PubMed  Google Scholar 

  12. Gorman AM et al. (1999) Antioxidant-mediated inhibition of the heat shock response leads to apoptosis. FEBS Lett 445: 98–102

    Article  CAS  PubMed  Google Scholar 

  13. Kol A et al. (1999) Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 103: 571–577

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Polla BS et al. (1998) Stress proteins in inflammation. Ann NY Acad Sci 851: 75–85

    Article  CAS  PubMed  Google Scholar 

  15. Landmesser U et al. (2002) Role of p47phox in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 40: 511–515

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ruiz-Ortega M et al. (2000) Angiotensin II activates nuclear transcription factor κB through AT1 and AT2 receptors in cultured vascular smooth muscle cells: molecular mechanisms. Circ Res 23: 1266–1272

    Article  Google Scholar 

  17. Egido J (1996) Vasoactive hormones and renal sclerosis. Kidney Int 49: 578–597

    Article  CAS  PubMed  Google Scholar 

  18. Wolf G and Nielson EG (1993) Angiotensin II as a renal growth factor. J Am Soc Nephrol 3: 1531–1540

    CAS  PubMed  Google Scholar 

  19. Diet F et al. (1996) Increased accumulation of tissue ACE in human atherosclerotic coronary artery tissue. Circulation 94: 2756–2767

    Article  CAS  PubMed  Google Scholar 

  20. Okamura A et al. (1999) Upregulation of renin-angiotensin system during differentiation from monocytes to macrophages. J Hypertens 17: 537–545

    Article  CAS  PubMed  Google Scholar 

  21. Rodríguez-Iturbe B et al. (2004) Oxidative stress, renal infiltration of immune cells and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 286: 606–616

    Article  Google Scholar 

  22. Wang D et al. (2003) Role of oxidative stress in endothelial dysfunction and enhanced responses to angiotensin II of afferent arterioles from rabbits infused with angiotensin II. J Am Soc Nephrol 14: 2783–2789

    Article  CAS  PubMed  Google Scholar 

  23. Wang D et al. (2004) Enhanced contractility of renal afferent arterioles from angiotensin-infused rabbits: roles of oxidative stress, thromboxane prostanoid receptors, and endothelium. Circ Res 94: 1436–1442

    Article  CAS  PubMed  Google Scholar 

  24. Ichihara A et al. (2004) Renal renin-angiotensin system. Contrib Nephrol 143: 117–130

    Article  PubMed  PubMed Central  Google Scholar 

  25. Navar LG (2004) The intrarenal renin-angiotensin system in hypertension. Kidney Int 65: 1522–1532

    Article  PubMed  Google Scholar 

  26. Navar LG et al. (2002) Regulation of intrarenal angiotensin II in hypertension. Hypertension 39: 316–322

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Navar LG and Nishiyama A (2004) Why are angiotensin concentrations so high in the kidney? Curr Opin Nephrol Hypertens 13: 107–115

    Article  CAS  PubMed  Google Scholar 

  28. Vanegas V (2005) Hypertension in Page (cellophane wrapped) kidney is due to interstitial nephritis. Kidney Int 68: 1161–1170

    Article  PubMed  Google Scholar 

  29. Kitiyakara C et al. (2003) Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol 14: 2775–2782

    Article  CAS  PubMed  Google Scholar 

  30. Nickenig G et al. (2000) Negative feedback regulation of reactive oxygen species on AT1 receptor gene expression. Br J Pharmacol 131: 795–803

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Wilcox CS (2005) Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol 289: 913–935

    Article  CAS  Google Scholar 

  32. Cai H and Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases: role of oxidant stress. Circ Res 87: 840–844

    Article  CAS  PubMed  Google Scholar 

  33. Forstermann U and Munzel T (2006) Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113: 1708–1714

    Article  PubMed  CAS  Google Scholar 

  34. Sydow K and Munzel T (2003) ADMA and oxidative stress. Atheroscler (Suppl 4): 41–51

  35. Kunsch C and Medford RM (1999) Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 85: 753–766

    Article  CAS  PubMed  Google Scholar 

  36. Schnackenberg CG (2002) Physiological and pathophysiological roles of oxygen radicals in the renal vasculature. Am J Physiol Regul Physiol 282: R335–R342

    Article  CAS  Google Scholar 

  37. Takahashi K et al. (1992) Glomerular actions of a free radical generated novel prostaglandin, 8-epi-prostaglandin F2 alpha: evidence for interaction with thromboxane A2 receptors. J Clin Invest 90: 136–141

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Kahler J et al. (2001) Oxidative stress increases endothelin-1 synthesis in human coronary artery smooth muscle cells. J Cardiovasc Pharmacol 38: 49–57

    Article  CAS  PubMed  Google Scholar 

  39. Touyz RM (2005) Reactive oxygen species as mediators of calcium signaling by angiotensin II: implications in vascular physiology and pathophysiology. Antioxid Redox Signal 7: 1302–1314

    Article  CAS  PubMed  Google Scholar 

  40. Meneton P et al. (2005) Links between dietary salt intake, renal salt handling, blood pressure and cardiovascular diseases. Physiol Rev 85: 679–715

    Article  CAS  PubMed  Google Scholar 

  41. Vaziri ND et al. (2002) Pathogenesis of lead-induced hypertension: role of oxidative stress. J Hypertension 20: S15–S20

    CAS  Google Scholar 

  42. Vaziri ND et al. (1999) Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension. Kidney Int 56: 1492–1498

    Article  CAS  PubMed  Google Scholar 

  43. Zalba G et al. (2001) Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction? Nephrol Dial Transplant 16 (Suppl 1): 2–5

    Article  CAS  PubMed  Google Scholar 

  44. Vaziri ND et al. (2003) Superoxide dismutase, catalase, glutathione peroxidase and NAD(P)H oxidase in lead-induced hypertension. Kidney Int 63: 186–194

    Article  CAS  PubMed  Google Scholar 

  45. Roberts CK et al. (2002) Effect of diet and exercise intervention on blood pressure, oxidative stress and nitric oxide availability. Circulation 106: 2530–2532

    Article  CAS  PubMed  Google Scholar 

  46. Roberts CK et al. (2000) Enhanced NO inactivation induced by a high fat, refined-carbohydrate diet. Hypertension 36: 423–429

    Article  CAS  PubMed  Google Scholar 

  47. Koo JR and Vaziri ND (2003) Effect of diabetes insulin and antioxidants on NO synthase abundance and NO interaction with reactive oxygen species. Kidney Int 63: 195–201

    Article  CAS  PubMed  Google Scholar 

  48. Schnackenberg CG et al. (1998) Normalization of blood pressure and renal vascular resistance in SHR with a membrane permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension 32: 59–64

    Article  CAS  PubMed  Google Scholar 

  49. Schnackenberg CG and Wilcox CS (2003) Two-week administration of tempol attenuates both hypertension and renal excretion of 8-iso prostaglandin f2 alpha. Hypertension 33: 424–428

    Article  Google Scholar 

  50. Vaziri ND et al. (2000) Effect of antioxidant therapy on blood pressure and NO synthase expression in hypertensive rats. Hypertension 36: 957–964

    Article  CAS  PubMed  Google Scholar 

  51. Chen X et al. (2001) Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 38: 606–611

    Article  CAS  PubMed  Google Scholar 

  52. Hong HJ et al. (2001) Supplementation with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. Hypertension 38: 1044–1048

    Article  CAS  PubMed  Google Scholar 

  53. Nava M et al. (2003) Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats. Am J Physiol Renal Physiol 284: 447–454

    Article  Google Scholar 

  54. Rodríguez-Iturbe B et al. (2003) Antioxidant-rich diet improves hypertension and reduces renal immune infiltration in spontaneously hypertensive rats. Hypertension 41: 341–346

    Article  PubMed  CAS  Google Scholar 

  55. Zahn DC et al. (2004) Upregulation of kidney NAD(P)H oxidase and calcineurin in SHR: reversal by lifelong antioxidant supplementation. Kidney Int 65: 219–227

    Article  Google Scholar 

  56. Beswick RA et al. (2004) NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 38: 1107–1111

    Article  Google Scholar 

  57. Beswick RA et al. (2001) Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 37: 781–786

    Article  CAS  PubMed  Google Scholar 

  58. Meng S et al. (2002) Superoxide dismutase and oxidative stress in Dahl salt-sensitive and resistant rats. Am J Physiol Regul Integr Comp Physiol 283: R732–R738

    Article  CAS  PubMed  Google Scholar 

  59. Lenda DM and Boegehold MA (2002) Effect of a high-salt diet on oxidant enzyme activity in skeletal muscle microcirculation. Am J Physiol Heart Circ Physiol 282: H385–H402

    Article  Google Scholar 

  60. Zhang Y et al. (2004) The antioxidant tempol prevents and partially reverses dexamethasone-induced hypertension in the rat. Am J Hypertens 17: 260–265

    Article  CAS  PubMed  Google Scholar 

  61. Vaziri ND et al. (1998) Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int 53: 1748–1754

    Article  CAS  PubMed  Google Scholar 

  62. Vaziri ND et al. (2002) Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in chronic renal insufficiency. Hypertension 39: 135–141

    Article  CAS  PubMed  Google Scholar 

  63. Vaziri ND et al. (2003) Oxidative stress and dysregulation of superoxide dismutase, NADPH oxidase and xanthine oxidase in renal insufficiency. Kidney Int 63: 179–185

    Article  CAS  PubMed  Google Scholar 

  64. Heitzer T et al. (1999) Increased NAD(P)H oxidase-mediated superoxide production in renovascular hypertension: evidence for an involvement of protein kinase C. Kidney Int 55: 252–260

    Article  CAS  PubMed  Google Scholar 

  65. Dobrian AD et al. (2001) Role of angiotensin II and free radicals in blood pressure regulation in a rat model of renal hypertension. Hypertension 38: 361–366

    Article  CAS  PubMed  Google Scholar 

  66. Barton CH et al. (2001) Enhanced nitric oxide inactivation in aortic coarctation-induced hypertension. Kidney Int 60: 1083–1087

    Article  CAS  PubMed  Google Scholar 

  67. Vaziri ND et al. (2000) Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension 36: 142–146

    Article  CAS  PubMed  Google Scholar 

  68. Zhou XJ et al. (2002) Nitric oxide synthase expression in hypertension induced by inhibition of glutathione synthase. J Pharmacol Exp Ther 300: 762–767

    Article  CAS  PubMed  Google Scholar 

  69. Ni Z et al. (2004) Lead exposure raises superoxide and hydrogen peroxide in human endothelial and vascular smooth muscle cells. Kidney Int 66: 2329–2336

    Article  CAS  PubMed  Google Scholar 

  70. Vaziri ND (2004) Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol 24: 469–473

    Article  CAS  PubMed  Google Scholar 

  71. Roberts CK et al. (2005) A high-fat, refined-carbohydrate diet induces endothelial dysfunction and oxidant/antioxidant imbalance and depresses NOS protein expression. J Appl Physiol 98: 203–210

    Article  CAS  PubMed  Google Scholar 

  72. Roberts CK et al. (2006) Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome. Metabolism 55: 928–934

    Article  CAS  PubMed  Google Scholar 

  73. Sindhu RK et al. (2005) Effects of aortic coarctation on aortic antioxidant enzymes and NADPH oxidase protein expression. Life Sci 7: 945–953

    Article  CAS  Google Scholar 

  74. Vaziri ND and Ni Z (2005) Expression of NOX-I, gp91phox, p47phox and P67phox in the aorta segments above and below coarctation. Biochim Biophys Acta 1723: 321–327

    Article  CAS  PubMed  Google Scholar 

  75. Mazzali M et al. (2003) Microvascular and tubulointerstitial injury associated with chronic hypoxia-induced hypertension. Kidney Int 63: 2088–2093

    Article  PubMed  Google Scholar 

  76. Tsukahara H et al. (2000) Increased oxidative stress in rats with chronic nitric oxide depletion: measurement of urinary 8-hydroxy-2′-deoxyguanosine excretion. Redox Rep 5: 23–28

    Article  CAS  PubMed  Google Scholar 

  77. Duarte J et al. (2002) Protective effects of the flavonoid quercetin in chronic nitric oxide deficient rats. J Hypertens 20: 1843–1854

    Article  CAS  PubMed  Google Scholar 

  78. Landmesser U et al. (2002) Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 106: 3073–3078

    Article  CAS  PubMed  Google Scholar 

  79. Rey FE et al. (2001) Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O2− and systolic blood pressure in mice. Circ Res 89: 408–414

    Article  CAS  PubMed  Google Scholar 

  80. Ungvari Z et al. (2004) Chronic high pressure-induced arterial oxidative stress. Am J Pathol 165: 219–226

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. McNally JS et al. (2003) Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am J Physiol Heart Circ Physiol 285: H2290–H2297

    Article  CAS  PubMed  Google Scholar 

  82. Hishikawa K et al. (1997) Pulsatile stretch stimulates superoxide production and activates nuclear factor-kappa B in human coronary smooth muscle. Circ Res 81: 797–803

    Article  CAS  PubMed  Google Scholar 

  83. Lacy F et al. (2000) Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity. Hypertension 36: 878–884

    Article  CAS  PubMed  Google Scholar 

  84. Dixon LJ et al. (2005) Increased superoxide production in hypertensive patients with diabetes mellitus: role of nitric oxide synthase. Am J Hypertens 18: 839–843

    Article  CAS  PubMed  Google Scholar 

  85. Roberts CK et al. (2006) Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9 and monocyte chemotactic activity in men with metabolic syndrome factors. J Appl Physiol 100: 1657–1665

    Article  CAS  PubMed  Google Scholar 

  86. Roggensack AM et al. (1999) Evidence for peroxynitrite formation in the vasculature of women with preeclampsia. Hypertension 33: 83–89

    Article  CAS  PubMed  Google Scholar 

  87. Duffy SJ et al. (1999) Treatment of hypertension with ascorbic acid. Lancet 354: 2048–2049

    Article  CAS  PubMed  Google Scholar 

  88. Nava M et al. (2003) Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats. Am J Physiol Renal Physiol 284: F447–F454

    Article  CAS  PubMed  Google Scholar 

  89. Müller DN et al. (2000) NF-κB inhibition ameliorates angiotensin II-induced renal damage in rats. Hypertension 35: 193–201

    Article  PubMed  Google Scholar 

  90. Alvarez V et al. (2002) Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells. Am J Physiol Renal Physiol 283: F1132–F1141

    Article  PubMed  Google Scholar 

  91. Beswick RA et al. (2001) Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 37: 781–786

    Article  CAS  PubMed  Google Scholar 

  92. Ding Y et al. (2001) Lead-induced hypertension. III. Increased hydroxyl radical production. Am J Hypertens 14: 169–173

    Article  CAS  PubMed  Google Scholar 

  93. Hong HJ et al. (2000) Suppression of the development of hypertension by the inhibitor of inducible nitric oxide synthase. Br J Pharmacol 131: 631–637

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Müller DN et al. (2002) Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 161: 1679–1693

    Article  PubMed  PubMed Central  Google Scholar 

  95. Park JB et al. (2002) Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats. Am J Hypertens 15: 78–84

    Article  CAS  PubMed  Google Scholar 

  96. Quiroz Y et al. (2001) Mycophenolate mofetil prevents the salt-sensitive hypertension resulting from short-term nitric oxide synthesis inhibition. Am J Physiol Renal Physiol 281: F38–F47

    Article  CAS  PubMed  Google Scholar 

  97. Rodríguez-Iturbe B et al. (2005) Early and sustained inhibition of nuclear factor kappa B prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther 315: 51–57

    Article  PubMed  CAS  Google Scholar 

  98. Rodríguez-Iturbe B et al. (2001) Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 59: 2222–2232

    Article  PubMed  Google Scholar 

  99. Rodríguez-Iturbe B et al. (2002) Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 282: F191–F201

    Article  PubMed  Google Scholar 

  100. Rodríguez-Iturbe B et al. (2003) Antioxidant-rich diet relieves hypertension and reduces renal immune infiltration in spontaneously hypertensive rats. Hypertension 41: 341–346

    Article  PubMed  CAS  Google Scholar 

  101. Tian N et al. (2005) Antioxidant treatment prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. Hypertension 45: 934–939

    Article  CAS  PubMed  Google Scholar 

  102. Rodríguez-Iturbe B et al. (2005) Hypertension induced by aortic coarctation above the renal arteries is associated with immune cell infiltration of the kidneys. Am J Hypertens 18: 1449–1456

    Article  PubMed  CAS  Google Scholar 

  103. Rodríguez-Iturbe B et al. (2004) Evolution of renal interstitial inflammation and NF-κB activation in spontaneously hypertensive rats. Am J Nephrol 24: 587–594

    Article  PubMed  CAS  Google Scholar 

  104. Kimmelstiel P and Wilson C (1936) Benign and malignant hypertension and nephrosclerosis: a clinical and pathological study. Am J Pathol 12: 45–81

    CAS  PubMed  PubMed Central  Google Scholar 

  105. Caetano EP et al. (1999) The clinical diagnosis of hypertensive nephrosclerosis—how reliable is it? Nephrol Dial Transplant 14: 288–290

    Article  CAS  PubMed  Google Scholar 

  106. Cannon PJ et al. (1966) Hyperuricemia in primary and renal hypertension. N Engl J Med 275: 457–464

    Article  CAS  PubMed  Google Scholar 

  107. Curtis JJ et al. (1988) Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med 85: 134–138

    Article  CAS  PubMed  Google Scholar 

  108. Kuster G and Ritz E (1989) Analgesic abuse and hypertension. Lancet 2: 1105

    Article  CAS  PubMed  Google Scholar 

  109. Weiss S and Parker F (1939) Pyelonephritis: its relation to vascular lesions and to arterial hypertension. Medicine 18: 221–315

    Article  Google Scholar 

  110. Caimi et al. (2000) Polymorphonuclear integrins, membrane fluidity, and cytosolic Ca2 content after activation in essential hypertension. Hypertension 36: 813–817

    Article  CAS  PubMed  Google Scholar 

  111. Dorffel Y et al. (1999) Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 34: 113–117

    Article  CAS  PubMed  Google Scholar 

  112. Suematsu M et al. (2002) The inflammatory aspect of the microcirculation in hypertension: oxidative stress, leukocytes/endothelial interaction, apoptosis. Microcirculation 9: 259–276

    Article  CAS  PubMed  Google Scholar 

  113. Mills PJ et al. (2003) Immune cell CD62 L and CD11a expression in response to a psychological stressor in human hypertension. Brain Behav Immun 17: 260–267

    Article  CAS  PubMed  Google Scholar 

  114. Boshtam M et al. (2002) Vitamin E can reduce blood pressure in mild hypertensives. Int J Vitamin Nutr Res 72: 309–314

    Article  CAS  Google Scholar 

  115. Duffy SJ et al. (2002) Prevention of hypertension, insulin resistance and oxidative stress by α-lipoic acid. Hypertension 39: 303–307

    Article  Google Scholar 

  116. Fotherby MD et al. (2000) Effect of vitamin C on ambulatory blood pressure and plasma lipids in older patients. J Hypertens 18: 411–415

    Article  CAS  PubMed  Google Scholar 

  117. Mullan B et al. (2002) Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes. Hypertension 40: 804–809

    Article  CAS  PubMed  Google Scholar 

  118. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto miocardico (GISSI) (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI Prevenzione trial. Lancet 354: 447–455

  119. Heart Protection Study Collaborative Group (2002) MRC/BHF heart protection study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360: 23–33

  120. Heart Outcomes Prevention Evaluation (HOPE) investigators (2000) Vitamin E supplementation and cardiovascular events in high risk patients. N Engl J Med 342: 154–160

  121. Stephens NG et al. (1996) Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347: 781–786

    Article  CAS  PubMed  Google Scholar 

  122. Albanes D et al. (1996) Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 6: 1560–1570

    Article  Google Scholar 

  123. Lee DH et al. (2004) Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? Am J Clin Nutr 80: 1194–1200

    Article  CAS  PubMed  Google Scholar 

  124. Roberts CK and Barnard RJ (2006) Effects of exercise and diet on chronic disease. J Appl Physiol 98: 3–30

    Article  Google Scholar 

  125. Kojda G and Hambrecht R (2005) Molecular mechanisms of vascular adaptations to exercise: physical activity as an effective antioxidant therapy. Cardiovasc Res 67: 187–197

    Article  CAS  PubMed  Google Scholar 

  126. Sironi L et al. (2004) Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. J Pharmacol Exp Ther 311: 989–995

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Dr Vaziri's work was partially supported by a grant from Heart, Lung and Blood Institute (H27485). Research in Dr Rodríguez-Iturbe's laboratory is supported by FONACIT Grant F-2005000283.

Author information

Authors and Affiliations

  1. Professor of Medicine, Physiology and Biophysics, and Chief of the Division of Nephrology and Hypertension, at the University of California, Irvine, CA, USA

    Nosratola D Vaziri

  2. Professor of Medicine at the Renal Service, Hospital Universitario, Universidad del Zulia, Instituto de Investigaciones Biomédicas (INBIOMED) in Maracaibo, Venezuela

    Bernardo Rodríguez-Iturbe

Authors
  1. Nosratola D Vaziri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernardo Rodríguez-Iturbe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nosratola D Vaziri.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vaziri, N., Rodríguez-Iturbe, B. Mechanisms of Disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Rev Nephrol 2, 582–593 (2006). https://doi.org/10.1038/ncpneph0283

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0283

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing